N-acetilcysteine prevents the <i>A</i>. <i>simplex</i> CE-induced TEER decrease. by Noelia Carballeda-Sangiao (2889611)

JNJ26993135 + BML-111 decreases permeability and enhances ZO-1 and claudin-1 induced by PAF but does not change TEER. by Kameljit K. Kalsi (16496511)

BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

GXM decreases the trans-endothelial electrical resistance (TEER) and transmigration of <i>C</i>. <i>neoformans</i> through HBECs in a blood brain barrier (BBB) model. by Hiu Ham Lee (15374677)

Data for subjects with significant slopes (regional progression or recovery colour coded, non-significant regions white) for the 4 data types over the study period. by Faran Sabeti (6166766)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Intention to treat (ITT) means (standard deviations) for outcome and process measures for all participants in the ACT (n = 52) and waitlist control (n = 46) groups. by Arianna Prudenzi (12436789)

Subjects:

Transepithelial electrical resistance (TEER) (N = 6). by Shirko Marcel Shokr (19173337)

“…<p><b>(A)</b> During the cultivation of SMC and ALI we observed significantly differences on day 18 (SMC: 9.61 kΩ*cm²; ALI: 7.73 kΩ*cm²; p<0.05) and day 25 (SMC: 8.19 kΩ*cm²; ALI: 6.44 kΩ*cm²; p<0.05) ALI cultures showed significantly decreased values compared to SMC. …”

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (sign... by Mobina Faqani (22783963)

Socio-demographic and baseline clinical characteristics of inulin-initiated T2DM patients at UoGCSH from 2015 to 2020 (N = 405). by Ashenafi Kibret Sendekie (12646960)

Subjects:

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)